title: Biological therapy for dermatological manifestations of inflammatory bowel disease.
abstract: Ulcerative colitis and Crohn's disease are the two forms of inflammatory bowel disease (IBD). The advent of biological drugs has significantly changed the management of these conditions. Skin manifestations are not uncommon in IBD. Among the reactive lesions (immune-mediated extraintestinal manifestations), erythema nodosum (EN) and pyoderma gangrenosum (PG) are the two major cutaneous ills associated with IBD, while psoriasis is the dermatological comorbidity disease observed more often. In particular, in the last few years, anti-tumor necrosis factor (TNF)-α agents have been successfully used to treat psoriasis, especially these kinds of lesions that may occur during the treatment with biological therapies. The entity of the paradoxical manifestations has been relatively under reported as most lesions are limited and a causal relationship with the treatment is often poorly understood. The reason for this apparent side-effect of the therapy still remains unclear. Although side effects may occur, their clinical benefits are undoubted. This article reviews the therapeutic effects of the two most widely used anti-TNF-α molecules, infliximab (a fusion protein dimer of the human TNF-α receptor) and adalimumab (a fully human monoclonal antibody to TNF-α), for the treatment of the major cutaneous manifestations associated with IBD (EN, PG and psoriasis).
authors.affiliation: Maddalena Zippi, Roberta Pica, Daniela De Nitto, Unit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, 00157 Rome, Italy.
authors.forename: Maddalena
authors.initials: M
authors.lastname: Zippi
authors.forename: Roberta
authors.initials: R
authors.lastname: Pica
authors.forename: Daniela
authors.initials: D
authors.lastname: De Nitto
authors.forename: Paolo
authors.initials: P
authors.lastname: Paoluzi
keywords: Biological therapies; Erythema nodosum; Inflammatory bowel disease; Psoriasis; Pyoderma gangrenosum